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Abbreviations {#nc005}
=============

6MWD

:   6 minute walking distance

6MWT

:   6 Minute Walk Test

AHF

:   acute heart failure

ATS

:   American Thoracic Society

BB

:   beta-blockers

CHF

:   chronic heart failure

EF

:   Ejection fraction

HR

:   Heart rate

HRQOL

:   health related quality of life

HS

:   Highly significant

MLWHFQ

:   Minnesota Living with Heart Failure Questionnaire

NS

:   Non significant

NYHA

:   New York Heart Association

QOL

:   quality of life

S

:   Significant

SAN

:   sino-atrial node

1. Introduction {#s0005}
===============

Acute heart failure (AHF) refers to rapid onset or worsening of symptoms and/or signs of HF. It is a life-threatening medical condition requiring urgent evaluation and treatment, typically leading to urgent hospital admission. AHF may present as a first occurrence (*de novo*) or, more frequently, as a consequence of acute decompensation of chronic HF (CHF) and may be caused by primary cardiac dysfunction or precipitated by extrinsic factors, often in patients with CHF [@b0005]. Acute myocardial dysfunction (ischemic, inflammatory, or toxic), acute valvular insufficiency, or pericardial tamponade are among the most frequent acute primary cardiac causes of AHF. Decompensation of CHF can occur without known precipitant factors, but more often with one or more factors, such as infection, uncontrolled hypertension, rhythm disturbances, or non-adherence with drugs/diet [@b0010]. The clinical presentation of AHF typically includes symptoms or signs related to congestion and volume overload rather than to hypoperfusion [@b0015]*.* Identification of precipitants/causes leading to decompensation that needs urgent management (acute coronary syndrome, hypertensive emergency, rapid arrhythmias or severe bradycardia/conduction disturbance, acute mechanical cause, or acute pulmonary embolism) are crucial for the proper management of AHF.

Sympathetic hyperactivity and consequent increase in the heart rate (HR) are physiological responses to low cardiac output in patients with AHF. However, elevated HR may become inappropriate in these patients, increasing myocardial oxygen consumption/demand and decreasing diastolic filling time and might lead to hemodynamic deterioration, ventricular dysfunction (tachycardiomyopathy) and clinical deterioration. Ivabradine has shown to increase survival of patients with stable systolic CHF. Compared with beta-blockers (BBs), ivabradine has the advantage of "pure" negative chronotropic effect \[increasing diastolic time through decrease of the spontaneous phase four depolarization in the sinoatrial node (SAN) action potential through blocking of the *I*~f~ channels present selectively in the SAN\] [@b0020], no effect on myocardial contractility [@b0020], and has been validated as a therapeutic option in patients with CHF [@b0025]. To the best of our knowledge, there are no studies published on the use of ivabradine in patients with AHF. Patients with HF have limited exercise tolerance; few pharmacological interventions have been proven effective in improving exercise capacity. Currently, there is conflicting evidence on the effectiveness of BBs on exercise capacity. Ivabradine has been shown to improve prognosis in patients with ischemic heart disease, left ventricular dysfunction, and HR ≥70 bpm [@b0030]. The association of ivabradine and atenolol has been proven effective in increasing exercise tolerance in patients with ischemic heart disease [@b0035].

The present study aimed to assess the efficacy and safety of ivabradine versus BBs as a strategy of HR control to improve exercise tolerance and quality of life in patients with AHF.

2. Patients and methods {#s0010}
=======================

The approval of the Ain Shams University (Cairo, Egypt) Ethical Committee was obtained according to the ethical guidelines of the 1975 Declaration of Helsinki as revised in 2008. A simple, randomized, prospective, case-control design was used for this study (simple randomization based on a single sequence of random assignments is known as simple randomization. This technique maintains complete randomness of the assignment of a subject to a particular group) [@b0040]. Patients admitted on Saturday, Monday, and Wednesday were categorized as Group 1, patients admitted on Sunday, Tuesday, and Thursday were categorized as Group 2. The study was conducted in Ain Shams University Hospitals (cardiac care units) from December 2017 through March 2018; it included patients with HR ≥80 bpm in sinus rhythm, hospitalized for AHF \[patients with recent onset or worsening of symptoms and/or signs of HF typically leading to urgent hospital admission, patients may present as a first occurrence (*de novo*) or as a consequence of acute decompensation of CHF, and may be caused by primary cardiac dysfunction or precipitated by extrinsic factors, often in patients with CHF\], New York Heart Association (NYHA) functional Class III or IV, and ejection fraction ≤40% [@b0045]. The study excluded patients with systolic blood pressure ≤85 mmHg (cardiogenic shock), persistent need of positive inotropes, acute myocarditis, primary valvular disease requiring surgery, atrial fibrillation/flutter, second/third-degree atrioventricular blockade, long QT syndrome, severe pulmonary disease, hepatic failure, creatinine ≥2.5 mg/dL, hemodialysis, or pregnancy/lactation.

Group 1, 50% of the study patients, were prescribed BBs up titrated, as tolerated, to the guideline recommended doses according to the type of BBs together with other anti-failure treatment. Group 2, 50% of the study patients, were prescribed ivabradine 5 mg twice daily with other anti-failure treatment. BBs were started when patients were weaned off intravenous (IV) inotropes, the lungs were dry, and HR was ≥80 bpm. Ivabradine was started once the patient was admitted with HR of ≥80 bpm and weaned off IV vasopressors (if any were used).

All study patients were subjected to 12-lead surface electrocardiogram. Echocardiographic assessment was performed by an expert blinded of the patient allocation in the study groups (using a GE Vivid S5N (HORTEN, NORWAY) version 10.3.0b.114 machine with an RS3 probe). Each patient was assessed for left ventricular ejection fraction using two-dimensional eye balling, left ventricular dimensions, segmental wall motion abnormalities, and diastolic function).

2.1. Functional capacity assessment {#s0015}
-----------------------------------

### 2.1.1. 6-minute walk test (6MWT) {#s0020}

The test was performed according to American Thoracic Society statement 2002 [@b0050] before treatment and after 1 month of follow-up. Prior to the test, the patient was advised to sit on a chair near the starting position where blood pressure/pulse was measured, baseline dyspnea/overall fatigue was recorded using the Borg scale [@b0055] ([Appendix 1](#s0005){ref-type="sec"}), and the worksheet was filled ([Appendix 2](#s0010){ref-type="sec"}). The scale was forwarded to the patient and the patient was asked to record his level (score) of shortness of breath and level (score) of fatigue using the scale. At the end of the exercise, the patient was reminded of the breathing score and fatigue score that he chose before the exercise and he was asked to grade both again. We used a 30-m walking corridor with marks on the wall every 3 m. The patient had to turn around at the end of the 30 m to complete one lap of 60 m at the starting line, which marks the beginning and end of each 60-m lap, and was marked on the floor using a tape [@b0055].

### 2.1.2. Minnesota Living With Heart Failure Questionnaire (MLWHFQ) {#s0025}

The MLWHFQ is a self-administered disease-specific questionnaire for patients with HF [@b0060], comprising 21 items rated on 6-point Likert scales, representing different degrees of impact of HF on health-related quality of life (HRQOL), from 0 (none) to 5 (very much). It provides a total score (range 0--105, from best to worst HRQOL) as well as scores for two dimensions, physical (8 items, range 0--40), and emotional (5 items, range 0--25). The other eight items (of the total of 21) are only considered for the calculation of the total score [@b0065]. Participating patients were asked to complete the MLWHFQ at baseline and at the end of the study. For each of the 21 questions, the patients were asked to indicate how much a possible effect of HF prevented them from living as they wanted during the past month (it is important to explain beforehand to patients that they should consider the past month to answer the questionnaires). The score of the physical dimension corresponds to the sum of eight questions (\# 2--7, 12, and 13) related to dyspnea and fatigue. The score of the emotional dimension is formed by five questions (\# 17--21). The remaining questions (\# 1, 8--11, and 14--16) plus the physical and emotional dimensions determined the total score. Higher scores indicate worse HRQOL ([Appendix 3](#s0040){ref-type="sec"}).

### 2.1.3. NYHA classification {#s0030}

\(1\) No limitation of physical activity, (2) slight limitation of physical activity, (3) marked limitation of physical activity, and (4) unable to carry on any physical activity without discomfort. (Symptoms of HF at rest) [@b0070].

2.2. Statistical analysis {#s0035}
-------------------------

Data were collected, revised, coded, and entered to the statistical package for social science (SPSS version 17; SPSS Inc., Chicago, IL, USA). Qualitative data were presented as *n* (%), whereas quantitative data were presented as mean, standard deviations, and ranges. The comparison between two groups with qualitative data was done by using Chi-square test, and Fisher exact test was used only when the expected count in any cell was less than five. The comparison between two paired groups with quantitative data and normally distributed data was done by using paired sample *t* test. The confidence interval was set at 95%, and the margin of error accepted was set at 5%. The *p* value was considered significant as the following: *p* \> 0.05, non-significant; *p* \< 0.05, significant; *p* \< 0.01, highly significant.

3. Results {#s0040}
==========

Male patients represented 80% and 70% of the study population in Groups 1 and 2, respectively (*p =* 0.89). As shown in [Table 1](#t0005){ref-type="table"}, demographics and baseline characteristics were matching in both groups, with exception of the prevalence of diabetes mellitus that was significantly higher in Group 2 (*p* = 0.03).Table 1Comparison between Groups 1 and 2 with regard to demographic data.Group 1\
*n* = 20Group 2\
*n* = 20Test value*p*SignificanceAge (y)Mean ± SD60.85 ± 11.4160.35 ± 11.080.141[b](#tblfn2){ref-type="table-fn"}0.889NSRange40--8631--87SexMales16 (80.0)14 (70.0)0.533[a](#tblfn1){ref-type="table-fn"}0.465NSFemales4 (20.0)6 (30.0)SmokingNon-smoker8 (40.0)9 (45.0)2.748[a](#tblfn1){ref-type="table-fn"}0.253NSSmoker11 (55.0)7 (35.0)Ex-smoker1 (5.0)4 (20.0)DMNegative13 (65.0)6 (30.0)4.912[a](#tblfn1){ref-type="table-fn"}0.027SPositive7 (35.0)14 (70.0)HTNNegative11 (55.0)10 (50.0)0.100[a](#tblfn1){ref-type="table-fn"}0.752NSPositive9 (45.0)10 (50.0)CHFNegative12 (60.0)14 (70.0)0.440[a](#tblfn1){ref-type="table-fn"}0.507NSPositive8 (40.0)6 (30.0)DyslipidemiaNegative11 (55.0)10 (50.0)0.100[a](#tblfn1){ref-type="table-fn"}0.752NSPositive9 (45.0)10 (50.0)BMI, kg/m^2^Mean ± SD28.80 ± 3.2430.00 ± 4.40−0.982[b](#tblfn2){ref-type="table-fn"}0.332NSRange25--3623--37EF eye-ballingMean ± SD31.25 ± 6.3531.75 ± 5.85−0.2590.797NSRange19--4018--40LVEDD, mmMean ± SD60.50 ± 9.4259.10 ± 9.210.4750.637NSRange47--8444--75LVESD, mmMean ± SD48.05 ± 10.1349.60 ± 9.54−0.4980.621NSRange36--7236--68Serum creatinine, mg/dLMean ± SD1.12 ± 0.341.42 ± 0.59−1.9750.056NSRange0.6--20.8--2.5INRMean ± SD1.12 ± 0.151.30 ± 0.40−1.8710.069NSRange1--1.50.9--2.1HB, gm/dLMean ± SD12.51 ± 2.1911.62 ± 1.541.4870.145NSRange7.5--169--14.7[^1][^2][^3][^4]

At baseline, there were no significant differences between both groups regarding the NYHA class, MLWHFQ, and the distance covered in the 6MWT with the assessment before and after the walk for the HR and Borg scale dyspnea/fatigue score, with the exception of Borg scale dyspnea/fatigue score before that showed significantly worse results in Group 1 (*p* = 0.02; [Table 2](#t0010){ref-type="table"}).Table 2Difference between two groups at baseline with regard to NYHA class, MLWHFQ, 6MWT distance, HR and Borg scale before and after 6MWT.BaselineGroup 1Group 2Test value[a](#tblfn3){ref-type="table-fn"}*p*SignificanceNYHA class314 (70.0)14 (70.0)0.0001.000NS46 (30.0)6 (30.0)MLWHFQ total scoreMean ± SD21.35 ± 26.5213.45 ± 22.141.023[b](#tblfn4){ref-type="table-fn"}0.313NSRange0--700--70HR before, bpmMean ± SD94.25 ± 13.3194.50 ± 12.13−0.062[b](#tblfn4){ref-type="table-fn"}0.951NSRange80--13080--130Borg dyspnea beforeMedian (IQR)4 (3--5)3 (3--4)−2.307[c](#tblfn24){ref-type="table-fn"}0.021SRange2--72--5Borg fatigue beforeMedian (IQR)4 (3--5)3 (3--4)−2.3070.021SRange2--72--56MWT distance, mMean ± SD138.00 ± 66.54135.50 ± 60.910.1240.902NSRange30--28020--230Premature termination of 6MWTNegative17 (85.0)16 (80.0)0.173[a](#tblfn3){ref-type="table-fn"}0.677NSDyspnea3 (15.0)4 (20.0)HR after, bpmMean ± SD120.50 ± 13.17120.75 ± 15.75−0.054[b](#tblfn4){ref-type="table-fn"}0.957NSRange100--150100--150Borg dyspnea afterMedian (IQR)8 (6--8)7 (6--8)−0.140[c](#tblfn24){ref-type="table-fn"}0.889NSRange4--105--10Borg fatigue afterMedian (IQR)8 (6--8)7 (6--8)−0.140[c](#tblfn24){ref-type="table-fn"}0.889NSRange4--105--10[^5][^6][^7][^8][^9]

There was no significant difference comparing length of hospital stay between both groups during the index admission. There were no recorded readmissions for enrolled patients during the period of follow-up; the length of stay for patients receiving BB (Group 1) was 6.85 ± 1.98 days (range, 4--10 days) and that for patients receiving ivabradine (Group 2) was 6.65 ± 2.25 days (range, 4--11 days), *p* = 0.617.

When used, BB up-titrated as part of optimum medical therapy for AHF resulted in a significant improvement in all the studied parameters (NYHA class; 6MWT distance; HR and Borg scale dyspnea/fatigue score before and after the walk), except for the premature termination of the 6MWT that did not reach statistical significance ([Table 3](#t0015){ref-type="table"}).Table 3Effect of BB therapy with regard to NYHA class, 6MWT distance, HR and Borg scale before and after 6MWT.Group 1BaselineEnd of follow-upTest value*p*SignificanceNYHA class10 (0)8 (42.1)35.264\<0.001HS20 (0)10 (52.6)314 (70.0)1 (5.3)46 (30.0)0 (0)HR before, bpmMean ± SD94.25 ± 13.3169.47 ± 6.858.981\<0.001HSRange80--13060--80Borg dyspnea beforeMedian (IQR)4 (3--5)2 (1--2)3.890\<0.001HSRange2--70--4Borg fatigue beforeMedian (IQR)4 (3--5)2 (1--2)3.890[c](#tblfn33){ref-type="table-fn"}\<0.001HSRange2--70--46MWT distance, mMean ± SD138.00 ± 66.54278.95 ± 107.447.813[b](#tblfn32){ref-type="table-fn"}\<0.001HSRange30--28080--400Premature termination of 6MWTNegative17 (85.0)19 (100.0)3.243[a](#tblfn31){ref-type="table-fn"}0.072NSDyspnea3 (15.0)0 (0.0)HR after, bpmMean ± SD120.50 ± 13.1793.95 ± 10.357.245[b](#tblfn32){ref-type="table-fn"}\<0.001HSRange100--5080--120Borg dyspnea afterMedian (IQR)8 (6--8)4 (4--5)3.856[c](#tblfn33){ref-type="table-fn"}\<0.001HSRange4--103--8Borg fatigue afterMedian (IQR)8 (6--8)4 (4--5)3.856[c](#tblfn33){ref-type="table-fn"}\<0.001HSRange4--103--8[^10][^11][^12][^13][^14]

When ivabradine 5 mg twice a day dose was used as part of optimum medical therapy for AHF resulted in a significant improvement in all the studied parameters (NYHA class; 6MWT distance; HR and Borg scale dyspnea/fatigue score before and after the walk) including the premature termination of the 6MWT ([Table 4](#t0020){ref-type="table"}). The MLWHFQ was significantly worse during the follow-up in both groups.Table 4Effect of ivabradine therapy with regard to NYHA class, 6MWT distance, HR and Borg scale before and after 6MWT.Group 2BaselineEnd of follow-upTest value*p*SignificanceNYHA class10 (0.0)7 (36.8)35.264[a](#tblfn5){ref-type="table-fn"}\<0.001HS20 (0.0)11 (57.9)314 (70.0)1 (5.3)46 (30.0)0 (0.0)HR beforeMean ± SD94.50 ± 12.1372.37 ± 6.538.340[b](#tblfn6){ref-type="table-fn"}\<0.001HSRange80--13060--85BORG dyspnea beforeMedian (IQR)3 (3--4)2 (1--2)3.919\<0.001HSRange2--51--3BORG fatigue beforeMedian (IQR)3 (3--4)2 (1--2)3.923[c](#tblfn37){ref-type="table-fn"}\<0.001HSRange2--51--36MWT distanceMean ± SD135.50 ± 60.91254.21 ± 6.2110.899[b](#tblfn6){ref-type="table-fn"}\<0.001HSRange20--230150--360Premature termination of 6MWTNegative16 (80.0)19 (100.0)4.234[a](#tblfn5){ref-type="table-fn"}0.039SDyspnea4 (20.0)0 (0.0)HR afterMean ± SD120.75 ± 15.7588.42 ± 9.737.843[b](#tblfn6){ref-type="table-fn"}\<0.001HSRange100--15070--110Borg dyspnea afterMedian (IQR)7 (6--8)5 (4--6)3.750[c](#tblfn37){ref-type="table-fn"}\<0.001HSRange5--103--7Borg fatigue afterMedian (IQR)7 (6--8)5 (4--6)3.750[c](#tblfn37){ref-type="table-fn"}\<0.001HSRange5--103--7[^15][^16][^17][^18][^19]

At the end of follow-up for 1 month, one case was missed to follow-up in each group. There were no recorded mortalities in both groups at the end of the study period. There were no significant differences between both groups regarding the NYHA class, MLWHFQ, and the distance covered in the 6MWT with the assessment before and after the walk for the HR and Borg scale dyspnea/fatigue score ([Table 5](#t0025){ref-type="table"}).Table 5Difference between two groups at the end of follow-up with regard to NYHA class, MLWHFQ, 6MWT distance, HR and Borg scale before and after 6MWT.End of follow-upGroup 1Group 2Test value[a](#tblfn7){ref-type="table-fn"}*p*SignificanceNYHA class18 (42.1)7 (36.8)0.1140.944NS210 (52.6)11 (57.9)31 (5.3)1 (5.3)MLWHFQ total scoreMean ± SD30.68 ± 13.7025.79 ± 11.661.186[b](#tblfn8){ref-type="table-fn"}0.243NSRange15--5512--55HR beforeMean ± SD69.47 ± 6.8572.37 ± 6.53−1.333[b](#tblfn8){ref-type="table-fn"}0.191NSRange bpm60--8060--85Borg dyspnea beforeMedian (IQR)2 (1--2)2 (1--2)−0.159[c](#tblfn34){ref-type="table-fn"}0.874NSRange0--41--3Borg fatigue beforeMedian (IQR)2 (1--2)2 (1--2)−0.315[c](#tblfn34){ref-type="table-fn"}0.753NSRange0--41--36MWT distanceMean ± SD278.95 ± 107.44254.21 ± 56.210.8890.380NSRange m80--400150--360Premature termination of 6MWTNegative20 (100.0)19 (100.0)NANANAHR afterMean ± SD93.95 ± 10.3588.42 ± 9.731.696[b](#tblfn8){ref-type="table-fn"}0.099NSRange bpm80--12070--110Borg dyspnea afterMedian (IQR)4 (4--5)5 (4--6)−1.526[c](#tblfn34){ref-type="table-fn"}0.127NSRange3--83--7Borg fatigue afterMedian (IQR)4 (4--5)5 (4--6)−1.526[c](#tblfn34){ref-type="table-fn"}0.127NSRange3--83--7[^20][^21][^22][^23][^24]

We did not observe any significant bradycardia, re-worsening of HF, arrhythmias, or drug-related significant side effects (including phosphines in the ivabradine arm).

4. Discussion {#s0045}
=============

To the best of our knowledge, this study was the first published work to compare ivabradine versus BB in AHF. The present study demonstrated that ivabradine administration was as effective as BB administration in patients with AHF.

The present study demonstrated that there was a significant reduction in resting HR after 4 weeks of treatment in both groups. The degree of reduction in resting HR in our study was comparable to the data from the The Systolic Heart Failure Treatment with the I*~f~* Inhibitor Ivabradine Trial (SHIFT study) subgroup (17.5 bpm reduction at 28 days in the sub-group with baseline resting HR ≥75 bpm) [@b0025].

In addition, our study assessed the effect of ivabradine on exercise tolerance and HR changes with exercise and showed significant beneficial effect of ivabradine on exercise HR. The present study confirmed favorable effects of ivabradine administration alone on functional capacity as there was a highly significant improvement in the NYHA class of the patients in the current study population (there was a shift of patients from NYHA classes III and IV to NYHA classes I and II). Clinical data supporting the effects of ivabradine in HF is provided by an improvement in physical performance and increase in exercise capacity with addition of ivabradine. The SHIFT trial has demonstrated the importance of HR reduction with ivabradine for improvement of clinical outcomes of HF symptoms [@b0025]*.* ETHIC-AHF (Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalized with heart failure and reduced left ventricular ejection fraction) study result showed a trend toward a better functional class observed in patients in the intervention group (ivabradine plus BB), versus the control group (BB only) who had NYHA class III or IV at 4 months [@b0075].

In the present study, the 6MWT distance improved significantly in both groups after treatment indicating an improvement in the functional performance, the consequence of which is an enhancement of daily activity and that can be reflected on improvement in mortality as shown by Alahdab et al. [@b0080]; they demonstrated that increasing the walking distance by 30 m was associated with reduced mortality risk of patients with HF irrespective of their age and NYHA class. According to LIVE:LIFE study, ivabradine was well tolerated and by 6 months, it was consistently associated with meaningful improvements in quality of life [@b0085].

We observed a worsened MLWHFQ score in \>50% of patients enrolled in the study; this was attributed to acute ischemic cardiomyopathy as an underlying etiology for their AHF. Interpretation of QOL questions was worse when compared with a month prior to their precipitating event. Nevertheless, there was a QOL improvement in patients who presented with acute on-top of CHF. Ivabradine provided an extra benefit as it lacks negative inotropic effect, which allowed earlier administration of therapy than BBs, which necessitates stable blood pressure and dry lung.

4.1. Limitations {#s0050}
----------------

This was a single-center study with a limited number of patients; however, the sample size was adequate for the study of the primary endpoint (efficacy and safety of ivabradine in AHF).

The relative predominance of male sex and the inclusion of all causes and precipitating factors of AHF in the study population may reduce the ability for generalising the results on AHF population.

BBs were used to the maximum tolerated dose, whereas dose of ivabradine was kept at 5 mg twice and was not up-titrated to the recommended 7.5 mg twice.

5. Conclusion {#s0055}
=============

The present study demonstrated the safety of the early use of ivabradine alone versus BBs when tolerated in patients admitted with AHF (both acutely decompensated as well as *de novo*). Patients in both groups achieved comparable reduction in HR with improvement in functional capacity and exercise tolerance.
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Appendix 1. The Borg scale. {#s0065}
===========================

0Nothing at all0.5Extremely weak (just noticeable)1Very weak2Weak (light)3Moderate4Somewhat strong5Strong (heavy)67Very strong8910Extremely strong (almost max)

Appendix 2. Worksheet used in the 6-minute walking test [@b0050]. {#s0070}
=================================================================
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Appendix 3. Minnesota Living with Heart Failure Questionnaire {#s0075}
=============================================================
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[^1]: Data are presented as *n* (%), mean ± SD, or range.

[^2]: BMI = body mass index; CHF = chronic heart failure; DM = diabetes mellitus; EF = ejection fraction; HB = hemoglobin; HS = highly significant; HTN = hypertension; INR = international normalized ratio; LVEDD = left ventricular end diastolic diameter; LVESD = left ventricular end systolic diameter; NS = non-significant; S = significant.

[^3]: Chi-square test.

[^4]: Independent *t* test.

[^5]: Data are presented as *n* (%) or mean ± SD and range.

[^6]: 6MWT = 6-minute walking test distance; HR = heart rate; HS = highly significant; IQR = interquartile range; MLWHFQ = Minnesota Living with Heart Failure Questionnaire; NS = non-significant; NYHA = New York Heart Association; S = significant.

[^7]: Chi-square test.

[^8]: Independent *t* test.

[^9]: Fisher exact test.

[^10]: Data are presented as *n* (%), mean ± SD, or range.

[^11]: 6MWT = 6-minute walking test distance; BB = beta-blockers; HR = heart rate; HS = highly significant; IQR = interquartile range; MLWHFQ = Minnesota Living with Heart Failure Questionnaire; NS = non-significant; NYHA = New York Heart Association; S = significant.

[^12]: Chi-square.

[^13]: independant t test.

[^14]: Fisher exact test.

[^15]: Data are presented as *n* (%), mean ± SD, or range.

[^16]: 6MWT = 6-minute walking test distance; HR = heart rate; HS = highly significant; IQR = interquartile range; MLWHFQ = Minnesota Living with Heart Failure Questionnaire; NS = non-significant; NYHA = New York Heart Association; S = significant.

[^17]: Chi-square test.

[^18]: Independent *t* test.

[^19]: Fisher exact test.

[^20]: Data are presented as *n* (%), mean ± SD, or range.

[^21]: 6MWT = 6-minute walking test distance; HR = heart rate; HS = highly significant; IQR = interquartile range; MLWHFQ = Minnesota Living with Heart Failure Questionnaire; NS = non-significant; NYHA = New York Heart Association; S = significant.

[^22]: Chi-square test.

[^23]: Independent *t* test.

[^24]: Fisher exact test.
